Core Insights - Moderna Inc. shares increased after reporting a narrower third-quarter loss than anticipated, indicating effective cost-cutting measures amid declining Covid vaccine sales [1][2] - The company aims to break even by 2028, despite a significant 45% year-over-year decline in third-quarter sales, which totaled $1 billion, primarily from its Covid vaccine [2][3] Financial Performance - The net loss for the third quarter was 51 cents per share, significantly better than Wall Street's expectation of a loss of $2.21 [1] - Third-quarter sales of $1 billion exceeded analysts' expectations, despite a 45% decline from the previous year [2] - Moderna's projected sales for the year are now between $1.6 billion and $2 billion, a reduction from the previous forecast that reached up to $2.2 billion [4] Market Context - Moderna shares rose 4.4% in premarket trading, although they have declined 43% year-to-date, contrasting with a nearly 16% gain in the S&P 500 index [3] - The company has faced challenges due to reduced demand for Covid vaccines and confusion surrounding federal vaccination policies [3][6] Regulatory Environment - The third quarter marked the beginning of the US vaccination season, revealing the impact of new guidelines that limit access to Covid vaccines [6] - The Advisory Committee on Immunization Practices recommended ending universal access to Covid shots, requiring individuals to consult medical professionals before vaccination [7]

Core Viewpoint - Moderna has reduced the upper limit of its 2025 revenue forecast by $200 million due to lower-than-expected sales of its COVID-19 vaccine in the U.S. market, as access to the vaccine has been a challenge for Americans [1] Company Summary - Moderna's adjustment in revenue forecast reflects a significant impact from the sales performance of its COVID-19 vaccine [1] - The company is facing challenges related to vaccine accessibility, which has contributed to the weaker sales figures [1]

Core Insights - Moderna reported a loss in the third quarter and experienced a decline in sales as it seeks to diversify its product offerings in response to decreasing demand for its Covid-19 vaccine [1] Financial Performance - The company logged lower sales figures in the third quarter compared to previous periods, indicating a significant impact from the waning demand for its Covid-19 vaccine [1] Strategic Direction - Moderna is actively working to expand its product range to mitigate the effects of reduced demand for its primary vaccine offering [1]

Exhibit 99.1 Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billion Increases 2025 expected year-end cash balance by $0.5 billion - $1 billion to a range of $6.5 - $7.0 billion CAMBRIDGE, MA / ACCESSWIRE / November 6, 2025 / ...

Core Insights - Moderna, Inc. reported third quarter revenue of $1.0 billion, with a GAAP net loss of $(0.2) billion and a GAAP EPS of $(0.51) [1] - The company narrowed its 2025 projected revenue range to $1.6 - $2.0 billion [1] - Expected GAAP operating expenses for 2025 were improved by $0.7 billion to a range of $5.2 - $5.4 billion [1] - The expected year-end cash balance for 2025 was increased by $0.5 billion - $1 billion to a range of $6.5 - $7.0 billion [1] - CEO Stéphane Bancel highlighted strong commercial and financial performance in Q3, driven by COVID vaccine sales and cost-reduction initiatives [1]

Core Insights - Moderna (MRNA) is expected to report Q3 2025 earnings on November 6, with sales estimated at $860 million and a loss of $2.15 per share, indicating a significant decline from the previous year [1] - The consensus estimate for loss per share has widened from $9.50 to $9.74 over the past month [1] Earnings Performance - Moderna has beaten earnings estimates in the last four quarters, with an average surprise of 37.78%, including a 28.76% surprise in the last reported quarter [2][3] Revenue Expectations - The majority of Q3 revenues are anticipated to come from COVID-19 vaccines, with combined sales estimated at $762 million, reflecting a significant decline due to reduced demand for boosters [5][6] - Minimal sales of the RSV vaccine, mResvia, are expected at $30 million, significantly lower than competitors GSK's Arexvy and Pfizer's Abrysvo [7] Pipeline Developments - Moderna is developing over 40 mRNA-based candidates across various clinical stages, with a focus on updates following the recent setback in the CMV vaccine program [8] - The pivotal Phase III study for mRNA-1647 failed to meet primary efficacy endpoints, leading to its discontinuation, although it continues to be studied in mid-stage trials [9] - Investors are also focused on mRNA-1083, a COVID-19/influenza combination vaccine, which is on track for FDA resubmission [10] - Intismeran autogene, a personalized cancer therapy developed with Merck, is undergoing pivotal studies, and updates on its progress are anticipated [11] Stock Performance and Valuation - Year-to-date, Moderna's shares have decreased by 40%, underperforming the industry and the S&P 500 [13][14] - The stock is trading at a premium valuation, with a price/sales ratio of 3.14 compared to the industry average of 2.33 [16] Investment Outlook - Despite significant declines in revenue, Moderna's cash position of approximately $7.5 billion allows for continued investment in pipeline development [18] - The recent CMV vaccine setback has raised concerns about the company's growth trajectory and reliance on other late-stage assets [19][20] - Plans to launch 10 new marketed products by 2028 targeting a market exceeding $30 billion are now clouded by the CMV failure and underwhelming sales of mResvia [21] - Current premium valuation and downward revisions to earnings estimates suggest caution for investors considering building positions in Moderna stock [22]

Core Insights - Moderna Inc's stock is experiencing a significant decline due to recent clinical setbacks overshadowing positive developments in its pipeline [1][2] - The company announced the dosing of the first patient in a Phase 1/2 study for mRNA-2808, a T-cell engager for multiple myeloma, but this was not enough to support the stock price [1] - The stock price fell 8.49% to $24.86, reflecting ongoing investor concerns [4] Clinical Developments - Moderna halted the Phase 3 trial for its cytomegalovirus vaccine, mRNA-1647, after it failed to meet its primary efficacy endpoint, leading to negative analyst reactions [2] - Analysts have adjusted their price targets, with UBS cutting its target to $40 and JPMorgan setting a target of $25 while maintaining an Underweight rating [2] Financial Outlook - The upcoming earnings report is anticipated, with consensus estimates projecting a quarterly loss of approximately $2.15 per share on revenue of about $860 million [3] - Current momentum score for Moderna is 12.67, indicating a negative price trend for the medium and long term [3]

Core Insights - Moderna, Inc. has initiated a Phase 1/2 study for its investigational mRNA-based T-cell engager, mRNA-2808, targeting relapsed or refractory multiple myeloma [1] Company Developments - The first patient has been dosed with mRNA-2808 at SCRI Oncology Partners in Nashville, Tennessee [1] - The study is being conducted in collaboration with the Sarah Cannon Research Institute [1]

Group 1 - The article discusses the potential for investors to position themselves in undervalued stocks that are mispriced by the market as October comes to an end [1] - Stone Fox Capital, based in Oklahoma, is led by Mark Holder, a CPA with extensive experience in investing and portfolio management [2] - The investing group "Out Fox The Street" provides stock picks, deep research, model portfolios, daily updates, and real-time alerts to help investors identify potential multibaggers while managing portfolio risk [2]

Core Insights - The Biotech Sector ETF (NASDAQ: IBB) has reached new multi-year highs, indicating strong performance in the sector [1][3] - The sector is characterized by both cyclical and non-cyclical elements, with diverse applications in biotechnology [4][5] Biotech Sector Overview - The biotechnology industry is categorized into various sectors, including red biotechnology (medical and pharmaceutical) and white biotechnology (industrial) [6][7][8] - Key players in red biotechnology include Eli Lilly (LLY) and AbbVie (ABBV), with ABBV investing in AI to enhance R&D and manufacturing [7] - Valero Energy (VLO) is noted as a leader in the biofuel space within white biotechnology [9] Market Trends and Predictions - The IBB chart shows a significant double bottom pattern formed in April 2022 and April 2025, suggesting potential upward movement [10] - A target price of 190 for IBB is considered reasonable over time, with interest in advanced areas like gene editing and AI-powered drug discovery [11] Company-Specific Developments - Pfizer has made headlines with a landmark agreement to lower prescription drug costs and an acquisition of Metsera, focusing on obesity and cardiometabolic treatments [14][15] - Moderna's stock rose 17% following reports of talks with a large drugmaker, indicating potential for significant developments in mRNA technology [19] - Technical analysis suggests that Moderna's stock could rise to $35 or higher if it maintains levels above $30 [22]